Washington Administrative Code › Title 246 - Health, Department of › PROFESSIONAL STANDARDS AND LICENSING › Chapter 246-945 - Pharmacy quality assurance commission › Part 1 - GENERAL PROVISIONS › Subpart C - Legend Drugs and Controlled Substances › Section 246-945-054 - Schedule III

Current through Register Vol. 24-14, July 15, 2024
The commission finds that the following substances have a
						potential for abuse less than the substances listed in Schedule I under
						RCW
						69.50.204 and WAC 246-945-051 and Schedule II
						under
						RCW
						69.50.206 and WAC 246-945-052, and have
						currently accepted medical use in treatment in the United States and that the
						abuse of the substances may lead to moderate or low physical dependency or high
						psychological dependency. In addition to substances listed in
						RCW
						69.50.208, the commission places each of the
						following drugs and other substances by whatever official name, common or usual
						name, chemical name, or brand name in Schedule III.
(1) Depressants. Unless specifically exempted
					 or unless listed in another schedule, any material, compound, mixture, or
					 preparation which contains any quantity of the following substances having a
					 depressant effect on the central nervous system: Perampanel, and its salts,
					 isomers, and salts of iso-mers.
(2)
					 Anabolic steroids. The term "anabolic steroid" means any drug or hormonal
					 substance, chemically and pharmacologically related to testosterone, other than
					 estrogens, proges-tins, and corticosteroids that promotes muscle growth, and
					 includes:
(a)
					 17alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane;
(b)
					 17alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane;
(c) 17alpha-methyl-delta1-dihydrotestosterone
					 (17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) some other names:
					 '17-alpha-methyl-1-testosterone';
(d) 19-nor-4,9(10)-androstadienedione
					 (estra-4,9(10)-dine-3,17-dione);
(e) Norandrostenediol:
(i) 19-nor-4-androstenediol (3alpha,
					 17beta-dihydroxye-str-4-ene);
(ii)
					 19-nor-4-androstenediol (3beta, 17beta-dihydroxye-str-4-ene);
(iii) 19-nor-5-androstenediol (3beta,
					 17beta-dihydroxye-str-5-ene);
(iv)
					 19-nor-5-androstenediol (3alpha, 17beta-dihy-droxyestr-5-ene).
(f) Norandrostenedione:
(i) 19-nor-4-androstenedione
					 (estr-4-en-3,17-dione);
(ii)
					 9-nor-5-androstenedione (estr-5-en-3,17-dione).
(g) Androstanediol:
(i)
					 3alpha,17beta-dihydroxy-5alpha-androstane;
(ii)
					 3beta,17beta-dihydroxy-5alpha-androstane.
(h) Boldione
					 (androsta-1,4-dine-3,17-dione);
(i)
					 Desoxymethyltestosterone (17alpha-methyl-5alpha-androst-2-en-17beta-ol); some
					 other names: 'madol'.
(j)
					 Mestanolone (17alpha-methyl-17beta-hydroxy-5al-pha-androstan-3-one);
(k) Methasterone
					 (2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);
(l) Prostanozol
					 (17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole).
(m) Any salt, ester, or isomer of a drug or
					 substance described or listed in this paragraph, if that salt, ester, or
					 iso-mer promotes muscle growth. Except such term does not include an anabolic
					 steroid which is expressly intended for administration through implants to
					 cattle or other nonhuman species and which has been approved by the secretary
					 of health and human services for such administration. If any person prescribes,
					 dispenses, or distributes such steroid for human use such person shall be
					 considered to have prescribed, dispensed, or distributed an anabolic steroid
					 within the meaning of this subsection.